Apogee Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022
Net Income	-83.99	-39.79
Depreciation & Amortization	0.09	0
Share-Based Compensation	6.1	2.14
Other Operating Activities	3.03	21.22
Operating Cash Flow	-74.76	-16.43
Capital Expenditures	-0.17	0
Change in Investments	-273.74	0
Investing Cash Flow	-273.91	0
Share Issuance / Repurchase	315.39	0
Other Financing Activities	-	168.32
Financing Cash Flow	315.39	168.32
Net Cash Flow	-33.28	151.89
Free Cash Flow	-74.93	-16.43
Free Cash Flow Per Share	-3.00	-6.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).